Both GIPR and GLP‐1R belong to the Class B1 GPCR family that is involved in glucose regulation and metabolic control, and both promote insulin secretion, though their mechanisms are different.[31] TZP, as the first GLP‐1R/GIPR dual agonist, significantly enhances weight loss and glycemic control through the simultaneous activation of both receptors.[32] Its mechanism might be related to the complementary nature of the signaling pathways of both receptors.[33] We assessed the expression of the dual receptors in the cell lines and in vivo tumor tissues involved in this study. Here, GLP1R is linked to neoplasm.